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Abstract
Background: During a global influenza pandemic, the vaccine requirements of developing countries can surpass
their supply capabilities, if these exist at all, compelling them to rely on developed countries for stocks that may not
be available in time. There is thus a need for developing countries in general to produce their own pandemic and
possibly seasonal influenza vaccines. Here we describe the development of a plant-based platform for producing
influenza vaccines locally, in South Africa. Plant-produced influenza vaccine candidates are quicker to develop and
potentially cheaper than egg-produced influenza vaccines, and their production can be rapidly upscaled. In this
study, we investigated the feasibility of producing a vaccine to the highly pathogenic avian influenza A subtype
H5N1 virus, the most generally virulent influenza virus identified to date. Two variants of the haemagglutinin (HA)
surface glycoprotein gene were synthesised for optimum expression in plants: these were the full-length HA gene
(H5) and a truncated form lacking the transmembrane domain (H5tr). The genes were cloned into a panel of
Agrobacterium tumefaciens binary plant expression vectors in order to test HA accumulation in different cell
compartments. The constructs were transiently expressed in tobacco by means of agroinfiltration. Stable transgenic
tobacco plants were also generated to provide seed for stable storage of the material as a pre-pandemic strategy.
Results: For both transient and transgenic expression systems the highest accumulation of full-length H5 protein
occurred in the apoplastic spaces, while the highest accumulation of H5tr was in the endoplasmic reticulum. The
H5 proteins were produced at relatively high concentrations in both systems. Following partial purification,
haemagglutination and haemagglutination inhibition tests indicated that the conformation of the plant-produced
HA variants was correct and the proteins were functional. The immunisation of chickens and mice with the
candidate vaccines elicited HA-specific antibody responses.
Conclusions: We managed, after synthesis of two versions of a single gene, to produce by transient and transgenic
expression in plants, two variants of a highly pathogenic avian influenza virus HA protein which could have vaccine
potential. This is a proof of principle of the potential of plant-produced influenza vaccines as a feasible pandemic
response strategy for South Africa and other developing countries.
Background
During 2009, South Africa was faced with the novel
(“swine”) influenza A H1N1 virus pandemic. As the
country does not have the ability to produce influenza
vaccine stocks, we had to rely on the World Health Or-
ganisation (WHO) and developed countries – and as
expected, even developed countries did not have ad-
equate vaccine stocks to meet their own demands.
Luckily, the 2009 H1N1 pandemic virus caused only
mild flu-like symptoms in most individuals. Certain
groups of people, however, were at greater risk for ser-
ious disease complications, such children and young
adults, people with diabetes, pregnant women and im-
munocompromised individuals [1]. Since South Africa
carries a high disease burden which includes one of the
highest Human immunodeficiency virus (HIV) preva-
lences in the world [2], this pandemic was a serious
warning for South Africa to have a contingency plan in
place for when the next influenza pandemic strikes.
Ideally, South Africa should be self-sufficient; producing
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tality in its large and relatively poor population.
Even routine seasonal influenza vaccine production by
the traditional egg-based technology is expensive and
slow, taking up to 6 months to complete from the notifi-
cation by WHO of suitable seasonal strains [3]. This is
not ideal for a pandemic situation, or for a developing
country with limited funds available. At a WHO meeting
in Cape Town in 2006, it was suggested that developing
countries will have to shift focus to alternative (i.e. cell-
based) vaccine production platforms to meet vaccine de-
mand [3]. Although these were not considered at the
time, plant expression systems have significant advan-
tages such as being safe, highly up-scalable and poten-
tially cost-effective. The disadvantages include potentially
complicated purification procedures and low recombin-
ant protein yields [4].
A number of studies have focussed on the expression
of various influenza antigens in plant systems, and spe-
cifically in tobacco plants (Nicotiana spp.). The influenza
virus surface haemagglutinin (HA) glycoprotein, which
elicits the primary neutralising immune response, is the
main target for vaccine development [5]. Shoji and col-
leagues [6] (2008) transiently expressed HA from H3N2
(A/Wyoming/03/03) which was targeted to the endoplas-
mic reticulum (ER), in Nicotiana benthamiana [6]. The
HA product yielded ~200 mg/kg fresh leaf weight (FW).
Mett et al. [7] also transiently expressed the A/Wyoming/
03/03 strain HA (stem domain and globular domain) and
neuraminidase (NA) proteins fused to the enzyme liche-
nase (LicKM) in N. benthamiana. The antigens were also
ER-targeted and yielded 100 mg HA/kg FW or 400 mg
NA/kg FW. The antigens produced in both of the above
studies elicited HA-specific immune responses in test
animals.
Shoji et al. [8] expressed a truncated version of plant
codon-optimised HA from H5N1 (A/Indonesia/05/05) in
N. benthamiana plants. This HA protein lacked the
transmembrane domain and native signal peptide, and
accumulated in the ER at a level of approximately
60 mg/kg FW. Spitsin and colleagues [9] expressed
H5N1 (A/Viet Nam/1203/2004) HA variants in plants,
implementing both apoplast and ER targeting for both
transient and stable transformation expression systems.
The variants included a full-length HA (aa 1–549), a
shortened version that contained the major antigenic
domains (aa 1–330), a C-terminal truncated version (aa
1–277) as well as a version lacking the N-terminal region
(aa 68–277). The 34 kDa C-terminal truncated variant
accumulated to the highest levels, up to 1 mg HA/kg
FW and 4 mg HA/kg FW for transient and stable trans-
formation expression systems, respectively. D’Aoust and
colleagues [10] expressed HA from the A/Indonesia/5/05
(H5N1) and the A/New Caledonia/20/99 (H1N1) strains
by means of agroinfiltration in N. benthamiana.T h eH A
was successfully expressed as virus-like particles (VLPs)
budding from the plasma membranes of the plant cells,
and accumulating between the plasma membrane and
the cell wall. The yield of HA was about 50 mg/kg FW.
All of the above studies confirmed that influenza HA
can be expressed to high levels in plants, and that this
plant-produced antigen can also induce HA-specific im-
mune responses in animals.
As a proof of concept that plant-produced influenza vac-
cines are feasible for South Africa, from early 2006 we fo-
cussed on attempting to produce the HA of the highly
pathogenic avian influenza virus (HPAIV) A/Viet Nam/
1194/2004 (H5N1). To date, HPAIV H5N1 is the most
virulent influenza strain, with a mortality rate of up to 60%
in humans (WHO website, http://www.who.int/) and up to
100% in domestic birds [11]. Although human-to-human
transmission is rare, the ability of H5N1 to infect humans
combined with its tendency to mutate is still considered to
be a serious global threat (http://www.who.int/). In this
study, we optimised the transient expression of full length
and truncated H5 HA variants in tobacco plants by means
of agroinfiltration. We investigated targeting of the HA
variants to different plant cell compartments: specifically,
to the apoplastic spaces, the ER, the chloroplast as well as
the cytosol. We also generated stable transgenic plant lines
expressing these HA variants by focusing on the expres-
sion constructs that produced high transient HA protein
concentrations. Immunogenicity trials with chickens and
mice were conducted to determine whether the HA pro-
teins were immunogenic, and haemagglutination and
haemagglutination-inhibition (HI) assays to determine
whether the proteins were correctly configured.
Results
Transient expression of H5 in tobacco plants
We compared the transient expression of eight H5N1 HA
constructs (see Table 1) in N. benthamiana plants. These
constructs successfully expressed both the full-length (H5)
Table 1 Summary of the clones constructed during the
project
Clones Cloning sites Plant cell compartment targetted
pTRAc-H5 AflIII and XbaI Cytosol
pTRAc-H5tr
pTRAERH-H5 NcoI and NotI ER
pTRAERH-H5tr
pTRACTP-H5 MIuI and XbaI Chloroplast
pTRACTP-H5tr
pTRAa-H5 NcoI and XbaI Apoplastic spaces
pTRAa-H5tr
The cloning sites as well as the targeted cell compartments are indicated.
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compartments tested (ER, chloroplast, cytosol and apo-
plastic spaces).
Expression time trials showed that optimum HA-
expression levels occurred at approximately 7 days
post infiltration (dpi). The engineered H5 and H5tr
proteins were expressed as the uncleaved HA0 form,
with products being approximately 70 kDa in size.
The transient expression levels as determined by
western blot for the various plant cell compartments
are shown in Figure 1. It is clear from the western
blot that the highest expression of full-length HA
(H5) occurred in the apoplastic spaces (lane 7), while
the highest accumulation of the truncated variant
(H5tr) occurred in the ER (lane 2). These results
were confirmed by three independent transient expression
experiments. When protein production was scaled up by
using the vacuum infiltration method on whole plants, we
focussed on the two high-yielding constructs, namely
pTRAa-H5 and pTRAER-H5tr. The H5 and H5tr proteins
generated by this method were quantitated on Coomassie-
stained gels after SDS-PAGE by comparison to known
BSA concentrations (Figure 2A). Crude extracts of the H5
and H5tr proteins were separated in lanes 8 and lane 9, re-
spectively. The expression levels obtained in these plant
extracts ranged from 62–130 mg H5/kg fresh weight (FW)
and 300–675 mg H5tr/kg FW.
In order to prepare plant-produced HA for animal trials,
ground plant extracts were clarified and diafiltered to en-
rich and concentrate HA and to perform a buffer ex-
change. Diafiltration reduced the concentration of plant
proteins, including RuBisCO (~ 55 kDa and 13 kDa subu-
nits), while retaining most of the HA protein (approxi-
mately 67 % final yield). The final product still contained
significant amounts of plant protein contaminants.
Apoplast-accumulated HA protein was selectively
extracted from N. benthamiana leaves 7dpi with pTRAa-
H5. This was accomplished by infiltrating the leaves with
buffer (PBS containing 0.1% Triton X-100) seven days after
the agroinfiltration. The buffer was then collected from
the cut edges of leaves by low speed centrifugation, effect-
ively extracting H5 protein from the apoplastic spaces (Fig-
ure 3). Immobilized metal affinity chromatography was
also successfully utilized to purify His-tagged H5tr protein
(results not shown); however, yields were low and could
not be reliably quantitated by SDS-PAGE analysis.
H5 expression in transgenic tobacco plants
Stably transformed N. tabacum plants were generated
with the pTRAa-H5 and pTRAERH-H5tr constructs.
Three T0 pTRAa-H5 lines and ten pTRAERH-H5tr lines
were allowed to self-pollinate, following which ~20 seeds
from each line were planted. All H5 plant lines (T1) were
PCR-positive indicating that all three plant lines probably
have multiple HA gene inserts, only three of the ten
H5tr plant lines were positive by PCR. These PCR posi-
tive plant lines were found to be positive for H5 or H5tr
protein expression by western blot analysis. Gene trans-
fer remained stable both in the second (T2) and third
generations (T3) of H5 and H5tr transgenic plants, while
these also successfully expressed H5 and H5tr, respect-
ively (Figure 4). The H5tr accumulation in the stable T3
transgenic plants ranged from 160 – 880 mg/kg, which
was lower than the levels obtained by transient expres-
sion. However, expression levels of H5 were higher in
the stably transformed transgenic plants (640–1440 mg/
kg) than in the transient expression system. The H5 pro-
tein from transgenic plants was concentrated and par-
tially purified (Figure 2B, lane 5) as described for the
transiently-expressed H5. The H5 enrichment is evident
when the processed extract is compared to the
crude plant extract (lane 4).
Haemagglutination and haemagglutination-inhibition (HI)
analyses
Haemagglutination and HI tests were conducted at the
National Institute of Communicable Diseases (NICD,
Sandringham, South Africa) a National Influenza Centre
for WHO, in order to determine the functionality of the
plant-produced HA protein variants. The crude pTRAa-
100 kDa 
70 kDa 
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Figure 1 Western blot analysis of H5 and H5tr transient expression in N. benthamiana, showing accumulation in various subcellular
compartments 7 days post infiltration. HA protein was detected using a primary rabbit anti-H5N1 polyclonal antibody. Crude plant extracts
were analysed from plant tissue infiltrated with Agrobacterium strains carrying the following expression vectors: Lane 1, pTRAERH-H5; lane 2,
pTRAERH-H5tr; lane 3, pTRAc-H5; lane 4, pTRAc-H5tr; lane 5, pTRACTP-H5; lane 6, pTRACTP-H5tr; lane 7, pTRAa-H5; lane 8, pTRAa-H5tr; lane 9,
protein ladder (Fermentas). The arrow indicates the position of the H5 and H5tr proteins.
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HI titre of 1:1024 against H5 antiserum (positive H5 in-
house control gave 1:512). The truncated H5tr product
gave a haemaglutination titre of 1:32; however, the HI
titre was inconclusive. The HI tests were repeated to
confirm the results.
Animal serum analysis
Western blot analysis of the serum obtained from H5-
and H5tr-immunised chickens showed that HA-specific
antibodies were present in all the chicken sera: data are
not shown due to the significant background signal
observed due to chicken antibodies strongly binding the
plant antigens present in the plant-produced HA pre-
parations. Sera from the PBS-immunized control animals
showed no reactivity to the HA protein.
From all the H5 and H5tr sera tested at the NICD, only
two H5tr serum samples inhibited haemagglutination by
control H5N1 virus during HI tests (titres of 1:32 and 1:8,
respectively) (Table 2). The H5 ELISA and HI analysis
performed by the Provincial Veterinary Laboratory were
negative for H5-specific antibodies – however, the
test was specific for an ostrich-derived low pathogenicity
H5N2 virus, indicating a lack of cross-reactivity.
Sera from mice that were vaccinated with the plant-pro-
duced H5 or H5tr were analysed by western blot utilising
a purified commercial H5 protein as antigen (Figure 5).
This analysis indicated that H5-specific antibodies were
present in the sera from all H5- (lanes 3–5) and H5tr-
(lanes 6–8) immunised mice. H5 specific antibodies were
absent in the control sera (from mice vaccinated with PBS
lane 9). However, HI assays performed with the mouse
sera were not conclusive, with only 3 of the mice vacci-
nated with full length H5 having antibody titres of 1:64
(Table 2).
Discussion
Plant-produced vaccines could be the way of the future
for pandemic influenza vaccine production, ever since
two different groups showed that production time for a
new H1N1 pandemic vaccine could be as short as one
month from the first announcement of the pandemic
strain sequence, to having the end-product ready for
testing in animals [12]. This is significantly shorter than
AB
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Figure 2 A) Coomassie-stained SDS-PAGE gel of transiently expressed H5 and H5tr. Crude, clarified extracts were prepared from N.
benthamiana leaves that were expressing the H5 and H5tr proteins transiently. The extracts were separated by SDS-PAGE and compared to
known BSA concentrations after staining with Coomassie Blue. Lane 1, prestained protein ladder (Fermentas); lane 2, 6.25 μg BSA; lane 3, 3.12 μg
BSA; lane 4, 1.56 μg BSA; lane 5, 0.78 μg BSA; lane 6, concentrated H5, lane 7 concentrated H5tr, lane 8, crude H5 extract, lane 9 crude H5tr
extract. The arrow indicates the position of the H5 protein. B) Coomassie-stained SDS-PAGE gel of H5 expressed in stable transgenic plants.
Apoplast-targeted H5 from transgenic plants was separated lanes 4 and 5. Lane 1, protein ladder (Fermentas); lane 2, 5 μg BSA; lane 3, 2.5 μg BSA;
lane 4, crude H5 extract; and lane 5, concentrated H5.
6 3 2 15 4
100kDa 
70kDa
Figure 3 Western blot analysis of HA products harvested from leaf apoplastic space extracts. N. benthamiana plants that were transiently
transformed with pTRAa-H5 were infiltrated with buffer, following which the buffer was collected by low-speed centrifugation. HA was detected
in the apoplastic space extracts using rabbit anti-H5N1 antibody. Lane 1, protein ladder (Fermentas); lane 2, wild type plant control; lanes 3 – 6,
H5 products of different pTRAa-H5-infiltrated leaf batches.
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seasonal vaccine made by egg-based technology. In
addition, compared to plant-produced vaccines, egg-
based vaccines also have the disadvantage that certain
strains, such as H5N1, do not grow well in eggs and pro-
duction is severely limited [3].
To illustrate the advantage for vaccine production via
transient plant expression, when a deadly H3N2 influenza
strain emerged in Brisbane, Australia (A/Brisbane/10/
2007), researchers at the Fraunhofer Institute (USA) took
36 days to produce a purified candidate vaccine via transi-
ent expression in tobacco plants (800 mg/kg fresh plant
material) [8]. In addition, a Canadian company (Medicago
Inc.) were able to obtain purified H1-VLPs within 21 days
after the initial pandemic H1N1 HA sequence became
known [13]. Medicago and the Fraunhofer Institute (USA)
also announced at the ‘Influenza Vaccine for the World
2009’ conference that human clinical trials will be imple-
mented for their plant-produced HA influenza vaccines.
These are currently in progress [14,15].
In our study, we aimed to establish a platform to pro-
duce influenza A virus subunit vaccines via tobacco
plants in South Africa, in order to minimise the impact of
a potential pandemic on our population. Pre-pandemic
awareness and stockpiling has also been encouraged and is
deemed necessary for H5N1 as it is still viewed as a po-
tential global pandemic threat due to its high mortality
rate [16]. In this case, stable transgenic seeds can be very
useful to have on standby in case of a H5N1 pandemic.
Our H5 and H5tr stable transgenic plant lines expressed
vaccine protein at high levels for two consecutive genera-
tions – which is a first for transgenic production of influ-
enza HA protein. When needed, these stored transgenic
seeds can be planted at large scale, and the resulting trans-
genic plants can be used to purify H5 vaccines within a
few weeks.
By targeting the HA variants to different plant cell com-
partments, we were able to determine which localities in
the plant cell had the highest potential for the accumula-
tion of our recombinant proteins. Our findings from both
the transient and the stable transgenic systems indicated
that full-length H5 accumulated at the highest level in the
apoplastic spaces. This may be due to the presence of the
HA transmembrane domain which can allow budding
from the cell membrane in the form of VLPs, as observed
by D’Aoust et al. [10]. In our study, the apoplast-targeted
HA also provided us with a potential alternative to leaf
homogenization which should reduce contaminating plant
proteins and simplify the purification process. We were
able to recover H5 protein from H5-expressing leaf tissue
by infiltrating leaves with a buffer containing a detergent
(Triton X-100), followed by low speed centrifugation of
whole leaves. By using this method we were also able to
extract H5 localised in the chloroplast or cytoplasm, but to
a lesser extent (data not shown). This was likely due to the
presence of Triton-X100 in the buffer, which allowed the
elution of intracellular proteins by solubilising the mem-
branes. This is an attractive alternative extraction method
especially for apoplast-accumulating proteins, as it mark-
edly reduces co-extraction of intracellular proteins and in-
soluble plant material.
H5tr accumulated at high levels in the ER. The ER is a
popular target for expression of recombinant proteins,
particularly glycoproteins, often resulting in high accu-
mulation levels [17]. The contrasting behaviour of H5tr
and H5 with respect to accumulation – the former high
in the ER and low in the apoplast, with the inverse for
H5 – is not easily explained. It is possible that SEKDEL-
tagged H5 is less stable than the H5tr equivalent.
In comparison to other studies investigating HA ex-
pression in plants [6-10] we obtained similar transient
100-
                 1 2 3             4             5            6             7 
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Figure 4 Western blot analysis showing HA expression in a representative sample of transgenic plant lines. Samples were harvested from
T3 plant lines that were transformed with pTRAa-H5 (lanes 2–4) or pTRAERH-H5tr (lanes 5–7). Lane 1, protein ladder (Fermentas).
Table 2 Summary of results obtained from chicken and
mouse sera analysis
Serum H5-specific
Western blot
HI test
H5-immunised chickens (n=4) + -
H5tr-immunised chickens (n=4 ) + +(n=2)
Control: PBS-immunised chickens
(n=2)
--
H5-immunised mice (n=10) + +(n=3)
H5tr-immunised mice (n=10 ) + -
Control: PBS-immunised mice (n=10) - -
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reported (1–800 mg/kg). Our choice of expression vec-
tor, infiltration methods and codon optimised HA gene
sequence can possibly account for our high HA accumu-
lation. Although immobilized metal affinity chromatog-
raphy (IMAC) purification (via His-tag) has previously
been successful for this protein [8], we could not utilize
the same purification strategy for our full-length H5, as
it did not contain a His-tag. We were able to purify the
His-tagged truncated H5 by IMAC; however, our yields
were too variable and too low for us to use the purified
material for animal experiments. We therefore decided
to generate our preliminary data using a crude concen-
trated and diafiltered product, in which the HA proteins
were enriched. More important, though, is not the
amount of protein produced, but the fact that the plant-
produced H5 protein exhibited the correct conformation
as shown by the success of HA and HI tests in compari-
sons with known standards.
The murine trial demonstrated the ability of plant-pro-
duced H5 and H5tr to induce HA-specific antibodies,
which was verified by western blot. The candidate H5 and
H5tr vaccines therefore elicited the correct antibody re-
sponse in vivo. However the HI titres were relatively low
for all the sera. Results for the sera of mice vaccinated with
H5 showed that only three had HI titres above 1:64 the
minimum HI titre considered to be protective in humans
is≥1:40 [18] which indicates that the plant-produced H5
in this study would have elicited a protective immunity.
The HI titres for mice vaccinated with H5tr were incon-
clusive. One of the reasons that the full length H5 did not
elicit high HI titres might be due to the extraction method
employed. The addition of Triton-X100 to the extraction
buffer possibly also destroyed any VLPs that were formed.
Western blot analysis of H5-immunised chicken sera
clearly demonstrated the presence of HA-specific anti-
bodies. HA-specific antibodies were also present in the
sera from H5tr-immunised chickens, but to a lesser degree.
In general, the antibody concentration was too low to in-
hibit haemagglutination of red blood cells during HI test-
ing, with the exception of two serum samples from the
H5tr-immmunised chickens (1:16 and 1:32). Even though
the HI titres were lower than 1:40 in both mice and chick-
ens immunised with H5tr, it still indicated that our candi-
date H5tr vaccine warrants further investigation.
HI titres were relatively low for all chicken and mice
sera: immune responses to our vaccine candidates may
have been suboptimal because of dose and adjuvant choice
(IFA). Other studies that have tested plant-produced HA
subunit vaccine candidates in animals have used various
influenza strains, regions of HA, purification protocols,
dosages, adjuvants and test animals - all which may play a
role in vaccine efficacy. In mice, Shoji et al. [6] tested three
doses ranging from 5 μgt o3 0μg together with 10 μgo f
Quil A adjuvant. D'Aoust [10] administered two doses of
0.5 μg H5-VLPs and Spitsin et al. [9] used two doses of
10 μg with alum-CpG adjuvant. When considering im-
munisation studies conducted on ferrets, the doses varied
from a 100 μg with alum adjuvant [7] to 45 and 95 μgH A
in Quil A adjuvant [8]. Ferrets, which are the preferred
animal model for influenza [19], were not available for our
study; we decided to conduct our vaccine trial on chickens
since these can be naturally infected by H5N1. We
deduced that our vaccine regimen (three doses of 13 μg
antigen) may have been too low to induce high antibody
titres in chickens. A dose-ranging study will be necessary
to determine the optimum antigen and adjuvant dosage.
As mentioned above, the full-length H5 antigen may not
have elicited high HI titres due to the presence of Triton-
X100 in the extraction buffer, which may have destroyed
any VLPs that were formed. D’Aoust [10] showed that low
doses of 0.5 μg VLPs protect against lethal challenge in
mice and that H5 antigen which did not form VLPs
induced up to six fold lower HI responses. It would be
interesting to determine if VLPs were formed in our study
and to develop extraction methods for them.
70
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Figure 5 Western blot indicating the presence of H5-specific antibodies in sera from mice immunised with plant-produced H5 or H5tr.
Purified H5N1 HA protein (Sino Biological) was detected using sera from H5-immunised mice (lanes 3–5), or H5tr-immunised mice (lanes 6–8).
Lane 1, protein ladder (Fermentas); lane 2, HA detection using anti-H5N1 HA mouse monoclonal antibody (1:5000, Abcam) and lane 9 is the
negative control where sera from animals vaccinated with PBS was used (dilution 1:4000). The arrow indicates the presence of the correct band
size in all the H5 and H5tr candidate vaccine sera samples.
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the plant-produced H5 or the H5tr showed the best po-
tential as a candidate subunit vaccine. Overall, a higher
concentration of H5-specific antibodies was detected in
chicken than in mouse sera; however, only two of the
H5tr chicken serum samples and three of the H5 mouse
serum samples gave low positive HI results.
Conclusions
Our findings indicate it is possible to produce influenza
subunit vaccines via plants in South Africa. The yields of
H5 and H5tr varied with experiment and by transgenic
plant line, but in general were higher than those
obtained by others: this may be due to the vector system
used, as well as to the human codon optimisation of the
genes. This is novel for HA genes in plants, and is based
on our previous observation of a significant yield im-
provement for HPV L1 proteins [20]. These yields should
make it economical to produce the H5 vaccine, even
given the fact that higher doses of novel influenza vac-
cines will probably be needed in comparison to the sea-
sonal vaccines [14]. We still need to give more attention
to downstream processing and especially purification
techniques, as large-scale end-stage production facilities
do not exist in South Africa. The study remains ongoing,
as we are still monitoring our stable transgenic plants to
determine whether gene integration remains stable over
the next few generations: this will determine whether or
not we will be able to establish a stable seedbank for
emergency large-scale vaccine production.
Methods
Strain selection and synthesis
After screening numerous AIV HA genes, the complete
HA gene (H5; 1 704 bp) of the A/Viet Nam/1194/2004
strain (H5N1, GenBank accession number: AY651333) was
selected to be the consensus amino acid sequence for
developing a candidate subunit vaccine. In addition, a 23
amino acid-truncated form of the H5 gene (H5tr; 1 635 bp)
was also engineered by removing the membrane-anchoring
domain coding region (nucleotides 1 597 – 1 665 bp). The
removal of the membrane-anchoring domain was intended
to prevent membrane insertion of the protein, making it
soluble and therefore aiding in purification. Both HA
variants (H5 and H5tr) were human-codon optimised
and synthesised (GENEART, Germany). Specific restric-
tion enzyme sites were added during gene synthesis to
facilitate cloning.
Construction of plant expression vectors
The H5 and H5tr genes were cloned into binary plant ex-
pression pTRA vectors, described previously [see 20,21 for
details]. These vectors are able to direct protein expression
to different plant cell compartments; namely, the cytoplasm
(pTRAc), chloroplast (pTRAkc-rbcs1-cTP), ER (pTRAkc-
ERH) and the apoplastic spaces (pTRAkc-A). The
pTRAkc-ERH vector added a 6 X histidine (His) C terminal
tag to facilitate purification. The apoplastic space-targeted
clones were created by cloning the HA genes into the
pTRAkc-ERH vector following removal of the His-tag and
ER retention signal (SEKDEL) sequences. See Table 1 for
cloning details and resulting clones.
Agrobacterium tumefaciens-mediated transient expression
The HA expression constructs were transformed into A.
tumefaciens GV3101(pM90RK) cells by electroporation
as described [20]. Recombinant Agrobacterium was
grown in LB media supplemented with 50 μg carbenicil-
lin/ml, 30 μg kanamycin/ml and 25 μg rifampicin/ml to
maintain selection of transformants.
Agrobacterium cultures containing the HA expression
constructs were cultured in induction medium (LB
broth, 10 mM MES, 20 μM acetosyringone and 2 mM
MgSO4, pH 5.6) containing antibiotics (50 μg carbenicil-
lin/ml, 30 μg kanamycin/ml and 25 μg rifampicin/ml) at
27°C overnight. In addition, the Agrobacterium LBA4404
(pBIN-NSs) strain (obtained from Marcel Prince, La-
boratory of Virology, The Netherlands) was also cul-
tured. This strain contains a silencing suppressor gene of
tomato spotted wilt virus (TSWV) to prolong and in-
crease recombinant gene expression [22]. Agrobacterium
was cultured to exponential phase (OD600=0.8) and
centrifuged at low speed (4000 x g). The pellet was
resuspended in infiltration buffer (10 mM MES, 10 mM
MgCl2, 150 μg acetosyringone/ml and 2% sucrose) and
left at room temperature for three hours. Each HA-con-
taining Agrobacterium strain was combined with
LBA4404 (pBIN-NSs) and diluted with infiltration buffer
to generate a final OD600 of 0.25 for each strain (total
Agrobacterium OD600 of the suspension was 0.5).
A time trial was conducted to determine the day with
the highest HA expression level. The Agrobacterium cul-
tures were co-infiltrated directly into the abaxial air
spaces of N. benthamiana leaves using a syringe. Infil-
trated N. benthamiana plants were grown at 22°C with
16 h light and 8 h dark cycles, with light intensity of 60–
80 μE/m
2/s. Five leaf disks (~ 8 mm diameter, ~ 13 μg)
were harvested from each plant at intervals for 8 days.
The leaf disks were ground in liquid nitrogen, followed
by the addition of 500 μl of Tris–HCl, pH8.
Larger scale expression studies were performed by vac-
uum infiltration of whole N. benthamiana plants (up to
20 plants) [20]. Vacuum infiltrated plants were harvested
and processed seven days post-infiltration. The infiltrated
leaves were ground in liquid nitrogen and suspended in
100 mM Tris–HCl pH 8 (1:2 ratio; mass: volume). HA
proteins that had accumulated in leaf apoplastic spaces
were recovered by vacuum or syringe infiltrating buffer
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lowing which the leaves were cut into strips about 2 cm
wide, layered on plastic grids and centrifuged at low
speed to liberate the protein eluate.
Nicotiana tabacum stable transformation and regeneration
N. tabacum L. ‘Petite Havana’ SR1 plants were cultivated
axenically on Murashige and Skoog (MS) media at 22°C
with 16 h-light and 8 h-dark photoperiod, at light inten-
sity of 60–80 μE/m
2/s. N. tabacum leaf discs were trans-
formed by binary expression vectors in A. tumefaciens
using standard techniques [20,23]. Based on high transi-
ent expression results, the ER-targeted constructs
(pTRAERH-H5 and pTRAERH-H5tr) and apoplast-tar-
geted constructs (pTRAa-H5 and pTRAa-H5tr) were
used for stable transformation. Rooted primary (T0)
transformants were transferred into soil, flowering plants
were self-pollinated and T1 seeds were collected. Primary
T1 progeny were selected on MS medium supplemented
with 120 μg/ml kanamycin. The plants were propagated
into T2 populations.
DNA was extracted from the first generation (T1)
transformed N. tabacum plants using the CTAB method
[24]. The DNA was screened by PCR for the presence of
the HA genes using internal gene primers, namely
H5SeqFw_633 5’ GACCAAGCTGTACCAGAACC 3’
and H5SeqRev_1132 5’ GCTCATTGCTGTGGTGGTA
3’, which produced a 518 bp fragment.
Twenty five plants were analysed for protein expres-
sion by western blots. Protein was extracted randomly
from five leaf disks. The plants that were positive for the
HA expression were self-fertilized to generate a homozy-
gous second generation and third generation plants.
Each generation was screened by PCR and followed by
western blot analysis.
Protein analysis and purification
For both transient and stable transgenic expression sys-
tems, the HA accumulation was evaluated by means of
western blotting. Crude plant extract was mixed with
SDS sample buffer, heated, and separated on 10% SDS-
PAGE gels. The gels were transferred to nitrocellulose
membranes by means of semi-dry electroblotting (Bio-
Rad). HA protein was detected using a primary rabbit
anti-H5N1 polyclonal antibody (1:500 dilution, GenBank
strain reference: AAT76166, US Biological) in conjunc-
tion with a secondary goat anti-rabbit antibody (1:7000,
Sigma). Nitro blue tetrazolium chlode/5-bromo-4
chloro-3-indolyl phosphate (NBT/BCIP) tablets (Roche)
were used as the detection substrate. To quantify the
amount of antigen produced, we compared the band
intensities of HA and known BSA concentrations on
Coomassie-stained SDS-PAGE gels by densitometry
(Gene Genius Bioediting system, Syngene).
The apoplast-targeted full-length H5 from T2 trans-
genic N. tabacum plants or from vacuum infiltrated
N. benthamiana plants was extracted using Dubecco’s
PBS (Sigma) containing 0.1% Triton –X100. The ER-
retained truncated H5 (H5tr) was extracted from vac-
uum infiltrated N. benthamiana plants using 100 mM
Tris–HCl, pH8. Generally, 20 g of leaf material was
ground up using a mortar and pestle in liquid nitrogen
and suspended in 40 ml extraction buffer (1:2 ratio;
mass: volume). Crude plant extracts were filtered
through Miracloth and clarified by centrifugation. HA
proteins were enriched and concentrated by diafiltration
into Dulbecco’s PBS (Sigma) using ultrafiltration hollow
fiber cartridges (50 kDa MWCO, Amersham Bios-
ciences). This resulted in buffer exchange of Tris–HCl to
PBS for H5tr and the removal of Triton-X100 from H5.
These HA proteins were subsequently used in the animal
trials. In addition, to capture the His-tagged H5tr pro-
teins, the crude extract of the ER-targeted H5tr protein
was filtered through Miracloth and then affinity purified
using Ni-NTA resin (Qiagen).
Haemagglutination and Haemagglutination inhibition
assays
Purified plant-produced HA protein samples (H5 and
H5tr) were freeze-dried and sent to the National Insti-
tute for Communicable Diseases (NICD) (Johannesburg,
South Africa) for haemagglutination and haemagglutin-
ation inhibition (HI) tests to determine their functional-
ity. Serial dilutions of known H5 antisera were tested
against our plant-produced protein or a standard dose
(4HAU/25 μl) of Influenza A (H5N1) control antigen
(obtained from CDC, Atlanta). After confirming the
functionality of the plant-produced HA proteins, animals
(chickens and mice) were vaccinated with these plant-
produced proteins and their sera were tested in a HI
assay against Influenza A (H5N1) control antigen
(4HAU/25 μl). Following incubation, a 0.5 % suspension
of Turkey red blood cells (RBC) was added and the test
interpreted by the inhibition of haemagglutination of
RBC. Influenza A (H3N2) and Influenza A (H1N1) anti-
gens were used as negative controls to determine
whether HI cross reaction was observed. Inactivated
antigens were obtained from Center for Disease Control
(CDC) in Atlanta, USA.
Animal trials and serum analysis
Ten Rhode Island Red male chickens (< 12 weeks old;
Provincial Veterinary Laboratory, Stellenbosch, South
Africa) were pre-bled three days prior to vaccination.
The chickens were divided into three groups with the
candidate vaccine groups (group 1 and 2) comprising of
four chickens each while the control group (group 3)
comprised of two chickens. Group 1 and 2 received a
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tein suspended in 1 ml Dubecco’s PBS mixed with in-
complete Freund’s adjuvant (IFA), at a 1:1 ratio. Group 1
received H5 and group 2 H5tr while group 3 received
Dulbecco’s PBS. Administration of the vaccines occurred
on day 0, 14, 28 and the chickens were sacrificed accord-
ing to the animal ethical code stipulated by UCT on day
42. Two weeks after each vaccination, a 1 ml blood sam-
ple was collected from each chicken. In addition to the
HI assays conducted at the NICD as described above,
the chicken sera were screened by HI assays and ELISA
using antibodies specific to a low pathogenicity H5N2
virus isolated from ostriches in South Africa.
In the mouse immunisation trial, thirty 7 week old
Balb/c mice were pre-bled three days prior to vaccin-
ation. The mice were separated into three groups of 10
mice per group. Group 1 and 2 were immunised with
8 μg (100 μl) plant-produced H5 from transgenic plants
and transiently expressed H5tr, respectively, each mixed
with IFA (1:1). Group 3 or the control group received
Dulbecco’s PBS. The candidate vaccine was admini-
strated intramuscularly to mice, 50 μl into each anterior
tibialis muscle. Four doses were administrated at two
weeks intervals (day 0, 14, 28 and 31) and blood was col-
lected before each dose, and 11 days after the final dose
when the animals were euthanized (day 42). The sera
were stored at −20°C for further analysis. The sera were
transported to the NICD for HI assays as described pre-
viously. All animal experiments were approved by the
UCT’s Animal Ethics committee (HSFAEC009/001).
To determine the presence of HA-specific IgG anti-
bodies, all the sera were screened by western blot. Plant-
produced H5 and H5tr protein was separated on an
SDS-PAGE gel and blotted onto nitrocellulose mem-
brane. Following protein transfer, the membrane was cut
into strips and probed with chicken sera (1:1000 dilu-
tions). After the washing steps, rabbit anti-chicken IgY
(IgG) antibody (Sigma) was used to determine whether
H5-specific antibodies were present. For the mouse sera,
human cell-expressed and purified H5 protein from (A/
VietNam/1194/2004) H5N1 (Sino Biological Inc) with
99% similarity to the plant expressed H5 was loaded onto
a gel and membrane strips were probed with 1:4000 sera
dilutions, and goat anti-mouse IgG (Sigma) secondary
antibody.
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